Ptc Therapeutics (PTCT) Revenue (2012 - 2026)

Ptc Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $272.6 million for Q1 2026.

• In Q1 2026, Revenue fell 76.83% year-over-year to $272.6 million; the TTM figure through Mar 2026 stood at $827.1 million (down 47.85% YoY), while the FY2025 annual figure was $1.7 billion, up 114.51% from the prior year.
• Revenue was $272.6 million for Q1 2026 at Ptc Therapeutics, up from $164.7 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $1.2 billion in Q1 2025 to a low of $148.7 million in Q1 2022.
• Historically, Revenue has averaged $266.2 million across 5 years, with a median of $210.6 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Revenue soared 459.73% in 2025, then plunged 76.83% in 2026.
• A 5-year view of Revenue shows it stood at $167.4 million in 2022, then soared by 83.41% to $307.1 million in 2023, then tumbled by 30.58% to $213.2 million in 2024, then decreased by 22.75% to $164.7 million in 2025, then jumped by 65.51% to $272.6 million in 2026.
• The last three Revenue figures came in at $272.6 million (Q1 2026), $164.7 million (Q4 2025), and $211.0 million (Q3 2025), per Business Quant data.